LeonaBio Q2 Results: 495 Patients Enrolled in Phase 3 ELAINE-3, Topline Data Expected 2H 2027
LONA has more than doubled off its 52-week low of $3.6 on light trading volume (0.3× avg).
Summary
LeonaBio reported Q2 2026 financials and updated its pivotal Phase 3 ELAINE-3 trial for lasofoxifene in ESR1-mutated metastatic breast cancer. Enrollment stands at 495 patients, on track to complete the ~600-patient study in Q4 2026 with topline data expected in 2H 2027. The company also highlighted up to $146 million in potential proceeds from cash-exercisable warrants issued in December 2025. This follows the Q1 2026 10-Q showing a 260% increase in net loss to $32.9 million and inability to access its $75 million ATM facility due to S-3 ineligibility. The warrant proceeds, if exercised, would materially extend the cash runway through the data readout. Key watch item: completion of enrollment in Q4 2026 and topline data in 2H 2027.
At the time of this announcement, LONA was trading at $7.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.8M. The 52-week trading range was $3.60 to $41.30. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.